LIPELLA PHARMACEUTICALS INC (LIPO)

US53630L1008 - Common Stock

2.31 -0.12 (-4.82%)

After market: 2.5876 +0.28 (+12.02%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates

		2021	2022	2023	2024	2025	2026
Revenue YoY % growth		259.35K -73.03%	184.16K -28.99%	449.62K 144.15%	287.64K -36.03%
EBITDA YoY % growth		N/A	N/A	-4.744M	N/A
EBIT YoY % growth		-1.916M -3,268.79%	-2.59M -35.17%	-4.746M -83.26%	-4.805M -1.25%
Operating Margin		-738.70%	-1,406.23%	-1,055.55%	-1,670.57%
EPS YoY % growth		N/A	N/A	N/A	-4.49

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates

	Q3 / 24
EPS Q2Q % growth	-0.98
Revenue Q2Q % growth	N/A
EBITDA Q2Q % growth	N/A
EBIT Q2Q % growth	-1.182M 12.87%

All data in USD

Recent Earnings VS Estimates Surprises (USD)

Period	Reported	Estimate	Difference	Surprise
Q2 2023 Q2Q % growth
Q1 2023 Q2Q % growth
Q4 2022 Q2Q % growth
Q3 2022 Q2Q % growth
Q4 2021 Q2Q % growth
Q3 2021 Q2Q % growth

Recent Revenue VS Estimates Surprises (USD)

Period	Reported	Estimate	Difference	Surprise
Q2 2024 Q2Q % growth	136.43K 27.89%			%
Q1 2024 Q2Q % growth	145.88K 23.57%			%
Q4 2023 Q2Q % growth	120.84K -19.98%			%
Q3 2023 Q2Q % growth	104.05K 213.88%			%
Q2 2023 Q2Q % growth
Q1 2023 Q2Q % growth
Q4 2022 Q2Q % growth
Q3 2022 Q2Q % growth
Q4 2021 Q2Q % growth
Q3 2021 Q2Q % growth

EPS and Revenue Revisions

	Next Q (1 month)	Next Q (3 month)	Next Year (1 month)	Next Year (3 month)
EPS	-700%	N/A	-700%	-1529.63%
Revenue	N/A	N/A	0%	93.15%